Rosmarinic Acid (Caffeic Acid Ester · Allergy Support · Neuroprotective)
| Compound | Rosmarinic Acid |
| Chemical class | Polyphenol — Caffeic Acid Ester (Caffeic Acid + 3,4-Dihydroxyphenyllactic Acid) |
| CAS | 20283-92-5 |
| Primary source | Rosmarinus officinalis (rosemary), Salvia officinalis (sage), Melissa officinalis (lemon balm), Perilla frutescens |
| Key applications | Anti-inflammatory, antioxidant, anxiolytic, allergy support |
| Claim strength | Moderate |
| Typical form | Rosemary extract standardised to rosmarinic acid; lemon balm extract |
| Buy from Herbuno | Rosemary Leaf Extract Powder → |
Name origin: Named after Rosmarinus officinalis (rosemary), the plant from which it was first isolated in 1958 by Scarpati and Oriente. Rosmarinic acid is a diester of caffeic acid and 3,4-dihydroxyphenyllactic acid — a more complex molecule than caffeic acid but sharing the core catechol-cinnamate pharmacophore. Traditional use: Rosemary, sage, and lemon balm have centuries of use in European herbal medicine for cognitive support, anti-inflammatory applications, nervous system calming, and digestive complaints. Rosmarinic acid is now understood to be a key bioactive contributor across these plants. Research trajectory: Rosmarinic acid has a well-developed preclinical evidence base and several human clinical studies for allergy/seasonal rhinitis (inhibiting IgE-related mast cell degranulation), cognitive function (Perilla extract studies), and anxiety management (lemon balm extract). Commercial source: Commercially available via rosemary leaf extract standardised to rosmarinic acid. See sourcing options below.
Evidence for Rosmarinic Acid Applications
Allergy and seasonal rhinitis: Rosmarinic acid inhibits complement system activation, IgE-mediated mast cell degranulation, and reduces histamine release in allergic models. Japanese RCTs using Perilla frutescens extract (rosmarinic acid-standardised) demonstrate significant reduction in seasonal rhinitis symptoms (nasal itching, tearing, sneezing) after 3–4 weeks. This is one of the more specific botanical anti-allergy evidence bases available. Claim strength: Moderate.
Cognitive function and neuroprotection: Rosmarinic acid inhibits acetylcholinesterase (AChE), Tau aggregation, and amyloid-beta fibrillation in vitro. Animal models show improved memory consolidation. Human studies with rosemary or lemon balm extract (rosmarinic acid-standardised) show modest improvements in memory speed and accuracy in healthy adults. Claim strength: Moderate.
Anti-inflammatory and antioxidant: Rosmarinic acid is a potent NF-κB inhibitor with dual cyclooxygenase and lipoxygenase inhibition. ORAC values are among the highest for hydroxycinnamic acid derivatives. In vivo anti-inflammatory efficacy across multiple animal models (arthritis, colitis, lung injury) is well-documented. Claim strength: Moderate.
Rosemary Leaf Extract Powder →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Allergy applications (Perilla RCTs): 50–200 mg/day rosmarinic acid (from Perilla frutescens extract) for 3–4 weeks during allergy season. Cognitive applications (lemon balm RCTs): 300–600 mg/day Melissa officinalis extract (standardised to rosmarinic acid) for mood and cognitive parameters. For general anti-inflammatory antioxidant applications, rosemary extract at 200–400 mg/day (10–20% rosmarinic acid) is a practical formulation range.
Specify rosemary extract by rosmarinic acid content (HPLC, minimum 5–20% depending on application). Herbuno’s Rosemary Leaf Extract Powder should be requested with rosmarinic acid quantification on CoA. Note: rosemary extract also contains carnosic acid and carnosol (diterpene phenols with potent antioxidant activity) — a full polyphenol profile CoA provides comprehensive characterisation of this multi-active extract.
Rosmarinic acid is water-soluble (better than most flavonoids). Relatively stable at acidic to neutral pH. Thermostable to 80°C. Compatible with tablet, capsule, and liquid formats. Tart-bitter taste in liquid formats requires flavour masking above 0.5% concentration.
Frequently Asked Questions — Rosmarinic Acid
Which plant is the best commercial source of rosmarinic acid?
Rosemary (Rosmarinus officinalis) is the most commercially established source, with well-characterised extract grades at 5–20% rosmarinic acid. Perilla frutescens has higher rosmarinic acid content per gram and is the source used in the Japanese allergy RCTs. Lemon balm (Melissa officinalis) is used for cognitive and anxiolytic applications. The choice of botanical source affects the co-constituent profile (carnosic acid in rosemary; apigenin/luteolin in Perilla) and the associated clinical evidence basis.
Is rosmarinic acid the same as rosemary extract used as a food antioxidant?
No. Rosemary extract used as a commercial food antioxidant (E392 in EU) is standardised primarily to carnosic acid and carnosol (diterpene phenols), not rosmarinic acid. Rosmarinic acid-standardised rosemary extract is a separate product specification used for supplement and nutraceutical applications. The two extract types from the same plant serve different functional purposes and should not be conflated in sourcing specifications.
Can rosmarinic acid be used for cat allergy or pet dander reactions?
The IgE-mediated mast cell inhibition and complement suppression mechanisms of rosmarinic acid are general across aeroallergen types — not specific to pollen. Clinical trials have used seasonal pollen as the allergen model, but the mechanism is applicable to cat dander and other IgE-driven allergic conditions. No specific RCT has evaluated rosmarinic acid for pet dander allergy specifically, but the mechanistic basis for positioning is sound.
Does rosemary extract with rosmarinic acid interact with anticoagulant medications?
Rosmarinic acid has mild platelet aggregation inhibitory activity (shared with many polyphenols) and mild anticoagulant properties in animal studies. At typical supplement doses (50–200 mg/day rosmarinic acid), clinically significant anticoagulant interactions are not well-documented in humans. Standard advisory language for individuals on warfarin or antiplatelet medications is appropriate as a precaution.
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery